
Friday, September 12, 2008 6:25:18 PM
Recent BOLT News
- Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 • GlobeNewswire Inc. • 03/25/2025 08:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/24/2025 08:31:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/24/2025 08:26:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2025 08:25:08 PM
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/24/2025 08:20:00 PM
- Bolt Biotherapeutics to Participate in Upcoming March Conferences • GlobeNewswire Inc. • 02/25/2025 09:05:00 PM
- Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. • GlobeNewswire Inc. • 02/11/2025 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2024 09:10:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:14:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2024 09:09:12 PM
- Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/12/2024 09:05:00 PM
- Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting • GlobeNewswire Inc. • 11/07/2024 03:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 09:38:58 PM
- Bolt Biotherapeutics Announces Changes to its Board of Directors • GlobeNewswire Inc. • 09/04/2024 08:05:00 PM
- Bolt Biotherapeutics to Participate in Upcoming September Conferences • GlobeNewswire Inc. • 08/28/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:10:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:08:26 PM
- Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:23:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 09:17:51 PM
- Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 07/12/2024 09:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:54:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:45:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 05:15:40 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/20/2024 05:22:14 PM
NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market • ELAB • Mar 27, 2025 11:20 AM
LaFleur Minerals Announces Memorandum of Understanding with Granada Gold on Milling Assessment for the Granada Gold Project Using the Beacon Gold Mill • LFLRF • Mar 27, 2025 8:40 AM
Nightfood Holdings (NGTF) Issues Shareholder Update on Imminent Strategic Acquisitions and Rapid Expansion in AI-Powered Hospitality Automation • NGTF • Mar 27, 2025 8:30 AM
ConnectM Secures Landmark Home and Building Electrification Project in India, Marking Strategic International Expansion • CNTM • Mar 27, 2025 7:05 AM
$SYNX - Could Silynxcom Be the Next 1000% Israeli Defense Tech Rocketship? (NYSE: SYNX) • SYNX • Mar 26, 2025 12:15 PM
ConnectM Issues Stockholder Letter from CEO & Chairman • CNTM • Mar 26, 2025 12:14 PM